Significantly, the finding of higher ApoB/ApoA1 ratio in late compared to early CKD reinforces the recommendation to use apolipoproteins, particularly ApoB/ApoA1 as novel tools for predicting lipid-related cardiovascular risk. This evidence concerns the gene APOB and chronic kidney disease.